|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1149633742 |
| 003 |
OCoLC |
| 005 |
20231120010446.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200412s2020 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d GZM
|d OCLCQ
|d OCLCF
|d EBLCP
|d UKAHL
|d UKMGB
|d UHL
|d OCLCO
|d OCLCQ
|d OCLCO
|d SFB
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBC009304
|2 bnb
|
| 016 |
7 |
|
|a 019682752
|2 Uk
|
| 019 |
|
|
|a 1150186357
|
| 020 |
|
|
|a 9780128199183
|q (electronic bk.)
|
| 020 |
|
|
|a 0128199180
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128196663
|
| 020 |
|
|
|z 0128196661
|
| 035 |
|
|
|a (OCoLC)1149633742
|z (OCoLC)1150186357
|
| 050 |
|
4 |
|a RS201.V43
|
| 082 |
0 |
4 |
|a 615.1
|2 23
|
| 245 |
0 |
0 |
|a Advances and avenues in the development of novel carriers for bioactives /
|c edited by Manju Rawat Singh [and others].
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Front Cover -- Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents -- Copyright Page -- Contents -- List of Contributors -- 1 Challenges and need of delivery carriers for bioactives and biological agents: an introduction -- 1.1 Introduction -- 1.2 Bioactives and biological agents -- 1.2.1 Phytoactives -- 1.2.2 Bioactive peptides -- 1.2.3 Bioactive lipids -- 1.2.4 Micronutrients -- 1.3 Therapeutic significance of bioactives -- 1.4 Need and challenges of delivery carriers for bioactives -- 1.4.1 Challenges in phytoactive delivery
|
| 505 |
8 |
|
|a 1.4.2 Challenges in protein and peptides delivery -- 1.4.2.1 Chemical modification -- 1.4.2.2 Delivery system -- 1.4.3 Challenges in vitamins delivery -- 1.5 Application of nanotechnology for the delivery of bioactives -- 1.5.1 Nanodelivery carriers for phytoactives or phytomedicines -- 1.5.1.1 Liposomes -- 1.5.1.1.1 Anticancer phytoactives -- 1.5.1.1.2 Antimicrobial phytomedicines -- 1.5.1.2 Niosomes -- 1.5.1.2.1 Antitumor phytoactive -- 1.5.1.2.2 Antiinflammatory phytoactive -- 1.5.1.3 Solid lipid nanoparticles -- 1.5.1.4 Polymeric nanoparticles -- 1.5.1.5 Metal-based nanoparticles
|
| 505 |
8 |
|
|a 1.5.2 Nanodelivery carrier for bioactive peptides/protein -- 1.5.2.1 Vaccines delivery -- 1.5.2.2 Hormone delivery: insulin -- 1.5.2.3 Enzyme delivery: digestive enzymes -- 1.5.2.4 Antimicrobial delivery -- 1.6 Toxicity and safety concern -- 1.7 Conclusion -- Declaration of interest -- References -- 2 Natural product-based nanomedicine: polymeric nanoparticles as delivery cargoes of food bioactives and nutraceuticals for ... -- 2.1 Problems with anticancer treatment -- 2.1.1 Tumor size -- 2.1.2 Toxicity -- 2.1.3 Hair loss -- 2.1.4 Nausea and vomiting -- 2.1.5 Leukopenia -- 2.1.6 Mucositis
|
| 505 |
8 |
|
|a 2.1.7 Drug resistance -- 2.1.8 Tumor stem cells -- 2.2 Overcoming drug resistance -- 2.3 Bioactive molecules found in functional foods and nutraceuticals: antitumor activity and chemotherapy treatment improvement -- 2.3.1 Caffeine -- 2.3.2 Catechins -- 2.3.3 Theobromine -- 2.3.4 Capsaicin -- 2.3.5 Sulforaphane -- 2.3.6 Apigenin -- 2.3.7 Resveratrol -- 2.4 Nanotechnology: an alternative way to improve natural products antitumor capacity through better molecules delivery -- 2.5 Physiological barriers: challenges for natural products target delivery
|
| 505 |
8 |
|
|a 2.6 Polymeric nanoparticles: use in the oncological area for the delivery of bioactive molecules -- References -- Further reading -- 3 The promising expedition of the delivery systems for monoclonal antibodies -- 3.1 Introduction -- 3.2 Monoclonal antibodies -- 3.2.1 Origins/types of monoclonal antibodies -- 3.2.2 Production methodologies -- 3.2.3 Functions and therapeutic applications of monoclonal antibodies -- 3.2.4 Checkpoints blockade monoclonal antibodies -- 3.3 Classic delivery systems for monoclonal antibodies
|
| 650 |
|
0 |
|a Drug carriers (Pharmacy)
|
| 650 |
|
0 |
|a Biomedical materials.
|
| 650 |
1 |
2 |
|a Drug Carriers
|0 (DNLM)D004337
|
| 650 |
|
6 |
|a Vecteurs de m�edicaments.
|0 (CaQQLa)000260399
|
| 650 |
|
6 |
|a Biomat�eriaux.
|0 (CaQQLa)201-0025723
|
| 650 |
|
7 |
|a Biomedical materials
|2 fast
|0 (OCoLC)fst00832586
|
| 650 |
|
7 |
|a Drug carriers (Pharmacy)
|2 fast
|0 (OCoLC)fst00898662
|
| 700 |
1 |
|
|a Singh, Manju Rawat.
|
| 776 |
0 |
8 |
|i Print version:
|t Advances and avenues in the development of novel carriers for bioactives.
|d London : Academic Press, 2020
|z 0128196661
|z 9780128196663
|w (OCoLC)1111976951
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128196663
|z Texto completo
|
